IP Library Assignment 017655/0436
Patent Assignment
Reel/Frame 017655/0436

Change of Name

Recorded: 2006-05-22 Pages: 4
Assignor
PROTEIN DESIGN LABS, INC.
Executed: 2006-01-09
Assignee
PDL BIOPHARMA, INC.
34801 CAMPUS DRIVE, FREMONT, CALIFORNIA, 94555
Covered Properties (33)
Bispecific Antibody Heterodimers
Patent: 5,932,448 →
Application: 07/801,798 →
Cross-Reacting Monoclonal Antibodies Specific for E- and P-Selectin
Patent: 5,622,701 →
Application: 08/259,963 →
Increasing Antibody Affinity by Altering Glycosylation in the Immunoglobulin Variable Region
Patent: 5,714,350 →
Application: 08/372,262 →
Bispecific Antibody Effective to Treat B-Cell Lymphoma and Cell Line
Patent: 6,129,914 →
Application: 08/397,411 →
Humanied Antibodies Reactive with Gpiib/Iiia
Patent: 5,777,085 →
Application: 08/458,516 →
Humanized Antibodies Reactive with L-Selectin
Patent: 6,210,671 →
Application: 08/579,378 →
Cross-Reacting Monoclonal Antibodies Specific for E-Selectin and P-Selectin
Patent: 6,210,670 →
Application: 08/619,491 →
Mutated Nonactivating IGG2 Domains and Anti-CD3 Antibodies Incorporating the Same
Patent: 5,834,597 →
Application: 08/656,586 →
Fas Ligand Fusion Proteins and Their Uses
Patent: 6,046,310 →
Application: 08/815,190 →
Antibodies with Increased Binding Affinity
Patent: 6,350,861 →
Application: 08/862,871 →
Humanized Antibodies to Gamma-Interferon
Patent: 6,329,511 →
Application: 09/450,520 →
Humanized Antibodies Against CD3
Patent: 7,381,803 →
Application: 09/618,380 →
Humanized Antibodies That Recognize Verotoxin Ii and Cell Line Producing Same
Patent: 7,846,435 →
Application: 09/700,851 →
Humanized Antibodies to Gamma-Interferon
Patent: 7,183,390 →
Application: 09/992,524 →
Publication: US 2002/0091240
Increasing Antibody Affinity by Altering Glycosylation of Immunoglobulin Variable Region
Patent: 6,933,368 →
Application: 10/084,825 →
Publication: US 2003/0054497
Anti-Hla-Dr Antibodies and the Methods of Using Thereof
Patent: 6,894,149 →
Application: 10/268,883 →
Publication: US 2003/0138862
Anti-CCR5 Antibody
Patent: 7,122,185 →
Application: 10/371,483 →
Publication: US 2003/0228306
Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
Patent: 7,288,248 →
Application: 10/383,447 →
Publication: US 2004/0096392
Humanized antibodies against CD3
Application: 10/435,299 →
Publication: US 2004/0052783
Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
Application: 10/676,476 →
Publication: US 2004/0115814
Alteration of Fcrn Binding Affinities or Serum Half-Lives of Antibodies by Mutagenesis
Patent: 7,217,797 →
Application: 10/687,118 →
Publication: US 2005/0032114
Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis
Patent: 7,276,589 →
Application: 10/724,274 →
Publication: US 2005/0054834
Methods of treatment of ulcerative colitis with anti-CD3 antibodies
Application: 10/729,795 →
Publication: US 2004/0253237
Amphiregulin Antibodies and Their Use to Treat Cancer and Psoriasis
Patent: 7,223,393 →
Application: 10/774,076 →
Publication: US 2004/0210040
Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies
Application: 10/805,562 →
Publication: US 2005/0019323
Methods of production and use of anti-integrin antibodies for the control of tissue granulation
Application: 10/818,068 →
Publication: US 2005/0002930
Alteration of Fcrn Binding Affinities or Serum Half-Lives of Antibodies by Mutagenesis
Patent: 7,361,740 →
Application: 10/822,300 →
Publication: US 2005/0014934
Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis
Patent: 7,285,268 →
Application: 10/830,956 →
Publication: US 2005/0163769
Therapeutic Use of Anti-CS1 Antibodies
Application: 10/842,011 →
Publication: US 2005/0025763
Alteration of Fc-Fusion Protein Serum Half-Lives by Mutagenesis
Patent: 7,217,798 →
Application: 10/966,673 →
Publication: US 2005/0226864
Therapeutic Use of Anti-CS1 Antibodies
Patent: 7,709,610 →
Application: 10/982,357 →
Publication: US 2006/0024296
Use of Anti-ALPHA5BETA1 Antibodies to Inhibit Cancer Cell Proliferation
Patent: 7,662,384 →
Application: 11/090,331 →
Publication: US 2005/0260210
Alteration of Fcrn Binding Affinities or Serum Half-Lives of Antibodies by Mutagenesis
Patent: 7,365,168 →
Application: 11/102,621 →
Publication: US 2005/0276799
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Nov 12, 1996
From: ANASETTI, CLAUDIO
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 008217/0886 →
Assignment of Assignor's Interest Nov 12, 1996
From: TSO, J. YUN; COLE, MICHAEL S.
To: PROTEIN DESIGN LABS, INCORPORATED
Reel/Frame 008216/0328 →
Assignment of Assignor's Interest Jan 30, 2002
From: MATSUMOTO, YOH-ICHI; IMAIZUMI, ATSUSHI; KIMURA, TSUYOSHI
To: TEIJIN, LIMITED
Reel/Frame 012349/0386 →
Assignment of Assignor's Interest Aug 13, 2003
From: BHASKAR, VINAY; CALLE, AGUSTIN DE LA; LAW, DEBBIE; CARAS, INGRID
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 014391/0598 →
Assignment of Assignor's Interest Aug 18, 2003
From: TSURUSHITA, NAOYA; HINTON, PAUL R.; VASQUEZ, MAXIMILLANO
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 014392/0780 →
Assignment of Assignor's Interest Aug 18, 2003
From: OLSON, WILLIAM C.; MADDON, PAUL J.
To: PROGENICS PHARMACEUTICALS, INC.
Reel/Frame 014393/0471 →
Assignment of Assignor's Interest Sep 25, 2003
From: VASQUEZ, MAXIMILIANO; LANDOLFI, NICHOLAS F.; TSURUSHITA, NAOYA; QUEEN, CARY L.
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 014562/0232 →
Corrective Assignment to Correct Serial Number 60086570. Previously Recorded on Reel 012527 Frame 0061. Oct 31, 2003
From: TEIJIN LIMITED
To: TEIJIN LIMITED; PROTEIN DESIGN LABS
Reel/Frame 014645/0806 →
Assignment of Assignor's Interest Jan 21, 2004
From: DUBRIDGE, ROBERT
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 014919/0940 →
Assignment of Assignor's Interest Oct 14, 2004
From: HINTON, PAUL R; TSURUSHITA, NAOYA; TSO, J. YUN; VASQUEZ, MAXIMILIANO
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 015250/0453 →
Assignment of Assignor's Interest Nov 19, 2004
From: RAMAKRISHNAN, VANITHA; POWERS, DAVID; JOHNSON, DALE E.; JEFFRY, URSULA
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 015376/0971 →
Assignment of Assignor's Interest May 22, 2006
From: MCPHATE GREEN, JENNIFER; TSO, J. YUN
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 017649/0446 →
Assignment of Assignor's Interest Feb 25, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 022310/0517 →
Assignment of Assignor's Interest Mar 4, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 022343/0269 →
Assignment of Assignor's Interest Mar 4, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 022343/0275 →
Assignment of Assignor's Interest Sep 18, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 023245/0973 →
Assignment of Assignor's Interest Dec 15, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 023649/0752 →
Change of Name Oct 13, 2010
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 025134/0725 →
Change of Name Dec 7, 2010
From: FACET BIOTECH CORPORATION
To: ABBOTT BIOTHERAPEUTICS CORP.
Reel/Frame 025445/0807 →
Change of Name Jul 13, 2011
From: FACET BIOTECH CORPORATION
To: ABBOTT BIOTHERAPEUTICS CORP
Reel/Frame 026587/0575 →
Assignment of Assignor's Interest Jan 15, 2013
From: PROGENICS PHARMACEUTICALS, INC.
To: CYTODYN, INC.
Reel/Frame 029633/0837 →
Change of Name Feb 18, 2013
From: ABBOTT BIOTHERAPEUTICS CORP
To: ABBVIE BIOTHERAPEUTICS INC.
Reel/Frame 029825/0070 →
Change of Name Feb 19, 2013
From: ABBOTT BIOTHERAPEUTICS CORP
To: ABBVIE BIOTHERAPEUTICS INC.
Reel/Frame 029834/0215 →
Change of Name Dec 20, 2013
From: ABBOTT BIOTHERAPEUTICS CORP
To: ABBVIE BIOTHERAPEUTICS INC.
Reel/Frame 031834/0936 →
Change of Name Aug 12, 2015
From: ABBOTT BIOTHERAPEUTICS CORP
To: ABBVIE BIOTHERAPEUTICS INC
Reel/Frame 036308/0865 →